�ݺ�ߣshows by User: bengggggg

�ݺ�ߣshows by User: bengggggg / http://www.slideshare.net/images/logo.gif �ݺ�ߣshows by User: bengggggg / Sat, 05 Oct 2024 09:18:54 GMT �ݺ�ߣShare feed for �ݺ�ߣshows by User: bengggggg Value of immune checkpoint blockade (ICB) in microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC) /slideshow/value-of-immune-checkpoint-blockade-icb-in-microsatellite-stable-mismatch-repair-proficient-mss-pmmr-metastatic-colorectal-cancer-mcrc/272203637 esmogeisler-241005091854-62ca1498
Background Adding ICB to cytotoxic chemotherapy is an emerging first-line treatment option for MSS/pMMR mCRC and/or selected subgroups. We aimed to quantify the value for money of alternating two cycles each of oxaliplatin-based chemotherapy (FLOX) and ICB (nivolumab), compared with standard-of-care FLOX alone, with and without biomarker-selected subgroups. Methods Individual participant data from METIMMOX-1, a phase II randomized controlled trial (n=76), were used to develop a partitioned survival model by parametrically fitting progression-free and overall survival. Health-related quality of life was determined via in-trial EQ-5D-5L surveys. Costs in 2023 Euros were estimated from a healthcare perspective and included drugs, tests, second-line and end-of-life care. We estimated the incremental cost-effectiveness ratio (ICER) for all randomized patients and for subgroups with the following cut-offs: ≥10% target lesion reduction at the first radiographic reassessment; C-reactive protein 8.0 mut/MB (the median value). Outcomes were discounted at 4% per year. Results Adding nivolumab for all patients provided 0.1175 quality-adjusted life years (QALYs) and incremental costs of >€75,000, yielding an ICER that is unlikely to be cost-effective. However, using biomarkers to select eligible patients doubled or tripled incremental QALYs while lowering incremental costs, leading to lower ICERs (Table). Conclusions Biomarker-guided selection for first-line ICB - compared to treating all unresectable MSS/pMMR mCRC patients - may improve incremental effectiveness while lowering incremental costs. The value of a TMB-based strategy is promising, and prospective validation is warranted. Clinical trial identification NCT03388190 (release date: 5 April, 2024). Legal entity responsible for the study University Hospital Akershus, Lørenskog, Norway. Funding Bristol Myers Squibb. Disclosure S. Meltzer: Financial Interests, Personal, Advisory Board: GSK. A.H. Ree: Financial Interests, Institutional, Funding: Bristol Myers Squibb; Financial Interests, Personal, Expert Testimony: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Takeda. All other authors have declared no conflicts of interest.]]>
Background Adding ICB to cytotoxic chemotherapy is an emerging first-line treatment option for MSS/pMMR mCRC and/or selected subgroups. We aimed to quantify the value for money of alternating two cycles each of oxaliplatin-based chemotherapy (FLOX) and ICB (nivolumab), compared with standard-of-care FLOX alone, with and without biomarker-selected subgroups. Methods Individual participant data from METIMMOX-1, a phase II randomized controlled trial (n=76), were used to develop a partitioned survival model by parametrically fitting progression-free and overall survival. Health-related quality of life was determined via in-trial EQ-5D-5L surveys. Costs in 2023 Euros were estimated from a healthcare perspective and included drugs, tests, second-line and end-of-life care. We estimated the incremental cost-effectiveness ratio (ICER) for all randomized patients and for subgroups with the following cut-offs: ≥10% target lesion reduction at the first radiographic reassessment; C-reactive protein 8.0 mut/MB (the median value). Outcomes were discounted at 4% per year. Results Adding nivolumab for all patients provided 0.1175 quality-adjusted life years (QALYs) and incremental costs of >€75,000, yielding an ICER that is unlikely to be cost-effective. However, using biomarkers to select eligible patients doubled or tripled incremental QALYs while lowering incremental costs, leading to lower ICERs (Table). Conclusions Biomarker-guided selection for first-line ICB - compared to treating all unresectable MSS/pMMR mCRC patients - may improve incremental effectiveness while lowering incremental costs. The value of a TMB-based strategy is promising, and prospective validation is warranted. Clinical trial identification NCT03388190 (release date: 5 April, 2024). Legal entity responsible for the study University Hospital Akershus, Lørenskog, Norway. Funding Bristol Myers Squibb. Disclosure S. Meltzer: Financial Interests, Personal, Advisory Board: GSK. A.H. Ree: Financial Interests, Institutional, Funding: Bristol Myers Squibb; Financial Interests, Personal, Expert Testimony: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Takeda. All other authors have declared no conflicts of interest.]]> Sat, 05 Oct 2024 09:18:54 GMT /slideshow/value-of-immune-checkpoint-blockade-icb-in-microsatellite-stable-mismatch-repair-proficient-mss-pmmr-metastatic-colorectal-cancer-mcrc/272203637 bengggggg@slideshare.net(bengggggg) Value of immune checkpoint blockade (ICB) in microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC) bengggggg Background Adding ICB to cytotoxic chemotherapy is an emerging first-line treatment option for MSS/pMMR mCRC and/or selected subgroups. We aimed to quantify the value for money of alternating two cycles each of oxaliplatin-based chemotherapy (FLOX) and ICB (nivolumab), compared with standard-of-care FLOX alone, with and without biomarker-selected subgroups. Methods Individual participant data from METIMMOX-1, a phase II randomized controlled trial (n=76), were used to develop a partitioned survival model by parametrically fitting progression-free and overall survival. Health-related quality of life was determined via in-trial EQ-5D-5L surveys. Costs in 2023 Euros were estimated from a healthcare perspective and included drugs, tests, second-line and end-of-life care. We estimated the incremental cost-effectiveness ratio (ICER) for all randomized patients and for subgroups with the following cut-offs: ≥10% target lesion reduction at the first radiographic reassessment; C-reactive protein <5.0 mg/L when starting ICB; and tumor mutational burden (TMB) >8.0 mut/MB (the median value). Outcomes were discounted at 4% per year. Results Adding nivolumab for all patients provided 0.1175 quality-adjusted life years (QALYs) and incremental costs of >€75,000, yielding an ICER that is unlikely to be cost-effective. However, using biomarkers to select eligible patients doubled or tripled incremental QALYs while lowering incremental costs, leading to lower ICERs (Table). Conclusions Biomarker-guided selection for first-line ICB - compared to treating all unresectable MSS/pMMR mCRC patients - may improve incremental effectiveness while lowering incremental costs. The value of a TMB-based strategy is promising, and prospective validation is warranted. Clinical trial identification NCT03388190 (release date: 5 April, 2024). Legal entity responsible for the study University Hospital Akershus, Lørenskog, Norway. Funding Bristol Myers Squibb. Disclosure S. Meltzer: Financial Interests, Personal, Advisory Board: GSK. A.H. Ree: Financial Interests, Institutional, Funding: Bristol Myers Squibb; Financial Interests, Personal, Expert Testimony: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Takeda. All other authors have declared no conflicts of interest. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/esmogeisler-241005091854-62ca1498-thumbnail.jpg?width=120&height=120&fit=bounds" /> Background Adding ICB to cytotoxic chemotherapy is an emerging first-line treatment option for MSS/pMMR mCRC and/or selected subgroups. We aimed to quantify the value for money of alternating two cycles each of oxaliplatin-based chemotherapy (FLOX) and ICB (nivolumab), compared with standard-of-care FLOX alone, with and without biomarker-selected subgroups. Methods Individual participant data from METIMMOX-1, a phase II randomized controlled trial (n=76), were used to develop a partitioned survival model by parametrically fitting progression-free and overall survival. Health-related quality of life was determined via in-trial EQ-5D-5L surveys. Costs in 2023 Euros were estimated from a healthcare perspective and included drugs, tests, second-line and end-of-life care. We estimated the incremental cost-effectiveness ratio (ICER) for all randomized patients and for subgroups with the following cut-offs: ≥10% target lesion reduction at the first radiographic reassessment; C-reactive protein 8.0 mut/MB (the median value). Outcomes were discounted at 4% per year. Results Adding nivolumab for all patients provided 0.1175 quality-adjusted life years (QALYs) and incremental costs of >€75,000, yielding an ICER that is unlikely to be cost-effective. However, using biomarkers to select eligible patients doubled or tripled incremental QALYs while lowering incremental costs, leading to lower ICERs (Table). Conclusions Biomarker-guided selection for first-line ICB - compared to treating all unresectable MSS/pMMR mCRC patients - may improve incremental effectiveness while lowering incremental costs. The value of a TMB-based strategy is promising, and prospective validation is warranted. Clinical trial identification NCT03388190 (release date: 5 April, 2024). Legal entity responsible for the study University Hospital Akershus, Lørenskog, Norway. Funding Bristol Myers Squibb. Disclosure S. Meltzer: Financial Interests, Personal, Advisory Board: GSK. A.H. Ree: Financial Interests, Institutional, Funding: Bristol Myers Squibb; Financial Interests, Personal, Expert Testimony: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Takeda. All other authors have declared no conflicts of interest.

Value of immune checkpoint blockade (ICB) in microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC) from University of Oslo

]]> 8 0 https://cdn.slidesharecdn.com/ss_thumbnails/esmogeisler-241005091854-62ca1498-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Why Is Health Care in the United States So Expensive? /slideshow/why-is-health-care-in-the-united-states-so-expensive/266787495 uscostseminar20240314-240314125803-ced6f34f
Healthcare costs in the U.S. might be of interest to many. The U.S. is an important non-European country for health economists and decision-analytic modelers because it is a large country in terms of its population size and an even larger market not just but also for health care services and goods. Also, much of not just basic but also translational research including HEOR comes out of the U.S. incl. the original idea for cost-effectiveness analysis. Regardless of whether you’re American or not, most people have pretty strong ideas about the U.S. Edvard de Bono, not the U2 singer but the originator of the term Lateral Thinking, famously said that the U.S. are not a country but an idea. This talk attempts to compare the United States’ health care expenditures and outcomes with others around the world; to highlight relevant recent controversies in the U.S. health policy debate related to costs; and to explore why U.S. care is so expensive (and what can be done about it).]]>
Healthcare costs in the U.S. might be of interest to many. The U.S. is an important non-European country for health economists and decision-analytic modelers because it is a large country in terms of its population size and an even larger market not just but also for health care services and goods. Also, much of not just basic but also translational research including HEOR comes out of the U.S. incl. the original idea for cost-effectiveness analysis. Regardless of whether you’re American or not, most people have pretty strong ideas about the U.S. Edvard de Bono, not the U2 singer but the originator of the term Lateral Thinking, famously said that the U.S. are not a country but an idea. This talk attempts to compare the United States’ health care expenditures and outcomes with others around the world; to highlight relevant recent controversies in the U.S. health policy debate related to costs; and to explore why U.S. care is so expensive (and what can be done about it).]]> Thu, 14 Mar 2024 12:58:03 GMT /slideshow/why-is-health-care-in-the-united-states-so-expensive/266787495 bengggggg@slideshare.net(bengggggg) Why Is Health Care in the United States So Expensive? bengggggg Healthcare costs in the U.S. might be of interest to many. The U.S. is an important non-European country for health economists and decision-analytic modelers because it is a large country in terms of its population size and an even larger market not just but also for health care services and goods. Also, much of not just basic but also translational research including HEOR comes out of the U.S. incl. the original idea for cost-effectiveness analysis. Regardless of whether you’re American or not, most people have pretty strong ideas about the U.S. Edvard de Bono, not the U2 singer but the originator of the term Lateral Thinking, famously said that the U.S. are not a country but an idea. This talk attempts to compare the United States’ health care expenditures and outcomes with others around the world; to highlight relevant recent controversies in the U.S. health policy debate related to costs; and to explore why U.S. care is so expensive (and what can be done about it). <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/uscostseminar20240314-240314125803-ced6f34f-thumbnail.jpg?width=120&height=120&fit=bounds" /> Healthcare costs in the U.S. might be of interest to many. The U.S. is an important non-European country for health economists and decision-analytic modelers because it is a large country in terms of its population size and an even larger market not just but also for health care services and goods. Also, much of not just basic but also translational research including HEOR comes out of the U.S. incl. the original idea for cost-effectiveness analysis. Regardless of whether you’re American or not, most people have pretty strong ideas about the U.S. Edvard de Bono, not the U2 singer but the originator of the term Lateral Thinking, famously said that the U.S. are not a country but an idea. This talk attempts to compare the United States’ health care expenditures and outcomes with others around the world; to highlight relevant recent controversies in the U.S. health policy debate related to costs; and to explore why U.S. care is so expensive (and what can be done about it).

Why Is Health Care in the United States So Expensive? from University of Oslo

]]> 94 0 https://cdn.slidesharecdn.com/ss_thumbnails/uscostseminar20240314-240314125803-ced6f34f-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Federated Learning /slideshow/federated-learning-254839221/254839221 federatedlearningwocoi-221209110357-01d7d1b8
Introductory talk for a mixed clinical and technical audience on federated learning with shallow and deep learning models in health and medicine]]>
Introductory talk for a mixed clinical and technical audience on federated learning with shallow and deep learning models in health and medicine]]> Fri, 09 Dec 2022 11:03:57 GMT /slideshow/federated-learning-254839221/254839221 bengggggg@slideshare.net(bengggggg) Federated Learning bengggggg Introductory talk for a mixed clinical and technical audience on federated learning with shallow and deep learning models in health and medicine <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/federatedlearningwocoi-221209110357-01d7d1b8-thumbnail.jpg?width=120&height=120&fit=bounds" /> Introductory talk for a mixed clinical and technical audience on federated learning with shallow and deep learning models in health and medicine

Federated Learning from University of Oslo

]]> 2061 0 https://cdn.slidesharecdn.com/ss_thumbnails/federatedlearningwocoi-221209110357-01d7d1b8-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 What Happens As A.I. Enters the Real World /slideshow/what-happens-as-ai-enters-the-real-world/254246533 aiinclinicalpracticetalk20221116bgwocoi-221116134122-7181bc74
What Happens As A.I. Enters the Real World - From a User Perspective]]>
What Happens As A.I. Enters the Real World - From a User Perspective]]> Wed, 16 Nov 2022 13:41:22 GMT /slideshow/what-happens-as-ai-enters-the-real-world/254246533 bengggggg@slideshare.net(bengggggg) What Happens As A.I. Enters the Real World bengggggg What Happens As A.I. Enters the Real World - From a User Perspective <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/aiinclinicalpracticetalk20221116bgwocoi-221116134122-7181bc74-thumbnail.jpg?width=120&height=120&fit=bounds" /> What Happens As A.I. Enters the Real World - From a User Perspective

What Happens As A.I. Enters the Real World from University of Oslo

]]> 42 0 https://cdn.slidesharecdn.com/ss_thumbnails/aiinclinicalpracticetalk20221116bgwocoi-221116134122-7181bc74-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Quo Vadis, Monkeypox? /slideshow/quo-vadis-monkeypox/251905314 caseserieswon-220602085710-72e1e4c4
Video at https://www.youtube.com/watch?v=f8HRluqOqDg 🙈🙉🙊 We discuss the clinical features on the basis of a case series from the U.K. and then have a Q&A with pox virologist and UpToDate author on the topic, Dr. Stuart Isaacs. Discussant: Stuart N. Isaacs, MD; Perelman School of Medicine at the University of Pennsylvania Host: Benjamin P. Geisler, MD MPH Recording date: May 30, 2022 0:00 Intro 1:09 Outline and Study Type 2:13 Background 5:31 Case Series 11:39 Q&A w/ Dr. Isaacs References: -Case series: Adler H et al. Lancet ID online early doi: 10.1016/S1473-3099(22)00228-6 -Comparison to Covid-19 case report/series: Rothe C et al N Engl J Med. 382(10); 970-1 doi: 10.1056/NEJMc2001468 https://pubmed.ncbi.nlm.nih.gov/32003... -Dr. Isaac’s UpToDate article: -Microbe.TV: This Week in Virology (TWiV) Special: Monkeypox clinical update with Dr. Daniel Griffin https://www.youtube.com/watch?v=dMiT7... -Program for Monitoring Emerging Diseases (ProMED) Monkeypox update (06), 30 May 2022: https://promedmail.org/ -Centre for Infectious Disease Research and Policy (CIDRAP): WHO says monkeypox containable, but nations should be on alert. https://www.cidrap.umn.edu/news-persp... -Phylogenetic trees: Hendrickson RC et al. Viruses 2010(2); 1933-67. doi: 10.3201/eid2409.171283 https://pubmed.ncbi.nlm.nih.gov/30124... -Virion schematics: ViralZone, from https://commons.wikimedia.org/wiki/Fi... -Discussion of on-going MPXV genome sequencing: https://virological.org/t/discussion-... -Genomic epidemiology of monkeypox virus: https://nextstrain.org/monkeypox?l=clock #monkeypox #virus ]]>
Video at https://www.youtube.com/watch?v=f8HRluqOqDg 🙈🙉🙊 We discuss the clinical features on the basis of a case series from the U.K. and then have a Q&A with pox virologist and UpToDate author on the topic, Dr. Stuart Isaacs. Discussant: Stuart N. Isaacs, MD; Perelman School of Medicine at the University of Pennsylvania Host: Benjamin P. Geisler, MD MPH Recording date: May 30, 2022 0:00 Intro 1:09 Outline and Study Type 2:13 Background 5:31 Case Series 11:39 Q&A w/ Dr. Isaacs References: -Case series: Adler H et al. Lancet ID online early doi: 10.1016/S1473-3099(22)00228-6 -Comparison to Covid-19 case report/series: Rothe C et al N Engl J Med. 382(10); 970-1 doi: 10.1056/NEJMc2001468 https://pubmed.ncbi.nlm.nih.gov/32003... -Dr. Isaac’s UpToDate article: -Microbe.TV: This Week in Virology (TWiV) Special: Monkeypox clinical update with Dr. Daniel Griffin https://www.youtube.com/watch?v=dMiT7... -Program for Monitoring Emerging Diseases (ProMED) Monkeypox update (06), 30 May 2022: https://promedmail.org/ -Centre for Infectious Disease Research and Policy (CIDRAP): WHO says monkeypox containable, but nations should be on alert. https://www.cidrap.umn.edu/news-persp... -Phylogenetic trees: Hendrickson RC et al. Viruses 2010(2); 1933-67. doi: 10.3201/eid2409.171283 https://pubmed.ncbi.nlm.nih.gov/30124... -Virion schematics: ViralZone, from https://commons.wikimedia.org/wiki/Fi... -Discussion of on-going MPXV genome sequencing: https://virological.org/t/discussion-... -Genomic epidemiology of monkeypox virus: https://nextstrain.org/monkeypox?l=clock #monkeypox #virus ]]> Thu, 02 Jun 2022 08:57:10 GMT /slideshow/quo-vadis-monkeypox/251905314 bengggggg@slideshare.net(bengggggg) Quo Vadis, Monkeypox? bengggggg Video at https://www.youtube.com/watch?v=f8HRluqOqDg 🙈🙉🙊 We discuss the clinical features on the basis of a case series from the U.K. and then have a Q&A with pox virologist and UpToDate author on the topic, Dr. Stuart Isaacs. Discussant: Stuart N. Isaacs, MD; Perelman School of Medicine at the University of Pennsylvania Host: Benjamin P. Geisler, MD MPH Recording date: May 30, 2022 0:00 Intro 1:09 Outline and Study Type 2:13 Background 5:31 Case Series 11:39 Q&A w/ Dr. Isaacs References: -Case series: Adler H et al. Lancet ID online early doi: 10.1016/S1473-3099(22)00228-6 -Comparison to Covid-19 case report/series: Rothe C et al N Engl J Med. 382(10); 970-1 doi: 10.1056/NEJMc2001468 https://pubmed.ncbi.nlm.nih.gov/32003... -Dr. Isaac’s UpToDate article: -Microbe.TV: This Week in Virology (TWiV) Special: Monkeypox clinical update with Dr. Daniel Griffin https://www.youtube.com/watch?v=dMiT7... -Program for Monitoring Emerging Diseases (ProMED) Monkeypox update (06), 30 May 2022: https://promedmail.org/ -Centre for Infectious Disease Research and Policy (CIDRAP): WHO says monkeypox containable, but nations should be on alert. https://www.cidrap.umn.edu/news-persp... -Phylogenetic trees: Hendrickson RC et al. Viruses 2010(2); 1933-67. doi: 10.3201/eid2409.171283 https://pubmed.ncbi.nlm.nih.gov/30124... -Virion schematics: ViralZone, from https://commons.wikimedia.org/wiki/Fi... -Discussion of on-going MPXV genome sequencing: https://virological.org/t/discussion-... -Genomic epidemiology of monkeypox virus: https://nextstrain.org/monkeypox?l=clock #monkeypox #virus <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/caseserieswon-220602085710-72e1e4c4-thumbnail.jpg?width=120&height=120&fit=bounds" /> Video at https://www.youtube.com/watch?v=f8HRluqOqDg 🙈🙉🙊 We discuss the clinical features on the basis of a case series from the U.K. and then have a Q&A with pox virologist and UpToDate author on the topic, Dr. Stuart Isaacs. Discussant: Stuart N. Isaacs, MD; Perelman School of Medicine at the University of Pennsylvania Host: Benjamin P. Geisler, MD MPH Recording date: May 30, 2022 0:00 Intro 1:09 Outline and Study Type 2:13 Background 5:31 Case Series 11:39 Q&A w/ Dr. Isaacs References: -Case series: Adler H et al. Lancet ID online early doi: 10.1016/S1473-3099(22)00228-6 -Comparison to Covid-19 case report/series: Rothe C et al N Engl J Med. 382(10); 970-1 doi: 10.1056/NEJMc2001468 https://pubmed.ncbi.nlm.nih.gov/32003... -Dr. Isaac’s UpToDate article: -Microbe.TV: This Week in Virology (TWiV) Special: Monkeypox clinical update with Dr. Daniel Griffin https://www.youtube.com/watch?v=dMiT7... -Program for Monitoring Emerging Diseases (ProMED) Monkeypox update (06), 30 May 2022: https://promedmail.org/ -Centre for Infectious Disease Research and Policy (CIDRAP): WHO says monkeypox containable, but nations should be on alert. https://www.cidrap.umn.edu/news-persp... -Phylogenetic trees: Hendrickson RC et al. Viruses 2010(2); 1933-67. doi: 10.3201/eid2409.171283 https://pubmed.ncbi.nlm.nih.gov/30124... -Virion schematics: ViralZone, from https://commons.wikimedia.org/wiki/Fi... -Discussion of on-going MPXV genome sequencing: https://virological.org/t/discussion-... -Genomic epidemiology of monkeypox virus: https://nextstrain.org/monkeypox?l=clock #monkeypox #virus

Quo Vadis, Monkeypox? from University of Oslo

]]> 115 0 https://cdn.slidesharecdn.com/ss_thumbnails/caseserieswon-220602085710-72e1e4c4-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Heterologous Boosters: "Mix and Match"? /slideshow/heterologous-boosters-mix-and-match/251301683 20220225bgbooster1cov-boostwon-220307165048
Journal club on the COV-BOOST study]]>
Journal club on the COV-BOOST study]]> Mon, 07 Mar 2022 16:50:47 GMT /slideshow/heterologous-boosters-mix-and-match/251301683 bengggggg@slideshare.net(bengggggg) Heterologous Boosters: "Mix and Match"? bengggggg Journal club on the COV-BOOST study <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/20220225bgbooster1cov-boostwon-220307165048-thumbnail.jpg?width=120&height=120&fit=bounds" /> Journal club on the COV-BOOST study

Heterologous Boosters: "Mix and Match"? from University of Oslo

]]> 130 0 https://cdn.slidesharecdn.com/ss_thumbnails/20220225bgbooster1cov-boostwon-220307165048-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 COVID-19: Hospitalist's Treatment Recommendations /slideshow/covid19-hospitalists-treatment-recommendations/247778097 hypoxemiainthewardpatientwithcovid-19therapeuticsbg20210422-210505081446
Video at https://www.youtube.com/watch?v=2rQKMD_5po0 Part of the "Hypoxemia in the Ward Patient with COVID-19" talks in Frederick Southwick's Coursera MOOC on COVID-19, "COVID-19 - A clinical update". "Dr. Ben Geisler, Hospitalist at Massachusetts General Hospital and Harvard Medical School faculty member reviews the current treatments for COVID-19. He first discusses the management of fluid replacement and diuretics, as well as the indications for bronchodilators and antibiotics. He emphasizes the importance of DVT anticoagulation prophylaxis. He next reviews the potential role of statins, evidence with regards angiotensin converting enzyme inhibitors, and NSAIDS. He next reviews the current indications for the agents of proven efficacy: Remdesivir and Dexamethasone. Finally he discusses the dilemma of equipoise and the best resources for staying up to date with this ever changing topic." In this iteration, we have added baricitinib and tocilizumab/IL-6 inhibitors.]]>
Video at https://www.youtube.com/watch?v=2rQKMD_5po0 Part of the "Hypoxemia in the Ward Patient with COVID-19" talks in Frederick Southwick's Coursera MOOC on COVID-19, "COVID-19 - A clinical update". "Dr. Ben Geisler, Hospitalist at Massachusetts General Hospital and Harvard Medical School faculty member reviews the current treatments for COVID-19. He first discusses the management of fluid replacement and diuretics, as well as the indications for bronchodilators and antibiotics. He emphasizes the importance of DVT anticoagulation prophylaxis. He next reviews the potential role of statins, evidence with regards angiotensin converting enzyme inhibitors, and NSAIDS. He next reviews the current indications for the agents of proven efficacy: Remdesivir and Dexamethasone. Finally he discusses the dilemma of equipoise and the best resources for staying up to date with this ever changing topic." In this iteration, we have added baricitinib and tocilizumab/IL-6 inhibitors.]]> Wed, 05 May 2021 08:14:45 GMT /slideshow/covid19-hospitalists-treatment-recommendations/247778097 bengggggg@slideshare.net(bengggggg) COVID-19: Hospitalist's Treatment Recommendations bengggggg Video at https://www.youtube.com/watch?v=2rQKMD_5po0 Part of the "Hypoxemia in the Ward Patient with COVID-19" talks in Frederick Southwick's Coursera MOOC on COVID-19, "COVID-19 - A clinical update". "Dr. Ben Geisler, Hospitalist at Massachusetts General Hospital and Harvard Medical School faculty member reviews the current treatments for COVID-19. He first discusses the management of fluid replacement and diuretics, as well as the indications for bronchodilators and antibiotics. He emphasizes the importance of DVT anticoagulation prophylaxis. He next reviews the potential role of statins, evidence with regards angiotensin converting enzyme inhibitors, and NSAIDS. He next reviews the current indications for the agents of proven efficacy: Remdesivir and Dexamethasone. Finally he discusses the dilemma of equipoise and the best resources for staying up to date with this ever changing topic." In this iteration, we have added baricitinib and tocilizumab/IL-6 inhibitors. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/hypoxemiainthewardpatientwithcovid-19therapeuticsbg20210422-210505081446-thumbnail.jpg?width=120&height=120&fit=bounds" /> Video at https://www.youtube.com/watch?v=2rQKMD_5po0 Part of the "Hypoxemia in the Ward Patient with COVID-19" talks in Frederick Southwick's Coursera MOOC on COVID-19, "COVID-19 - A clinical update". "Dr. Ben Geisler, Hospitalist at Massachusetts General Hospital and Harvard Medical School faculty member reviews the current treatments for COVID-19. He first discusses the management of fluid replacement and diuretics, as well as the indications for bronchodilators and antibiotics. He emphasizes the importance of DVT anticoagulation prophylaxis. He next reviews the potential role of statins, evidence with regards angiotensin converting enzyme inhibitors, and NSAIDS. He next reviews the current indications for the agents of proven efficacy: Remdesivir and Dexamethasone. Finally he discusses the dilemma of equipoise and the best resources for staying up to date with this ever changing topic." In this iteration, we have added baricitinib and tocilizumab/IL-6 inhibitors.

COVID-19: Hospitalist's Treatment Recommendations from University of Oslo

]]> 165 0 https://cdn.slidesharecdn.com/ss_thumbnails/hypoxemiainthewardpatientwithcovid-19therapeuticsbg20210422-210505081446-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Trends of Cost-Effectiveness Over Time /slideshow/trends-of-costeffectiveness-over-time/235080232 finaln-200605231914
Pre-ASCO Seminar: (Re)Defining Value in Cancer Care: Priorities for Patients, Providers, and Health Systems Panel: International Experience with Health Technology Assessment (HTA) & Lessons for the United States,]]>
Pre-ASCO Seminar: (Re)Defining Value in Cancer Care: Priorities for Patients, Providers, and Health Systems Panel: International Experience with Health Technology Assessment (HTA) & Lessons for the United States,]]> Fri, 05 Jun 2020 23:19:14 GMT /slideshow/trends-of-costeffectiveness-over-time/235080232 bengggggg@slideshare.net(bengggggg) Trends of Cost-Effectiveness Over Time bengggggg Pre-ASCO Seminar: (Re)Defining Value in Cancer Care: Priorities for Patients, Providers, and Health Systems Panel: International Experience with Health Technology Assessment (HTA) & Lessons for the United States, <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/finaln-200605231914-thumbnail.jpg?width=120&height=120&fit=bounds" /> Pre-ASCO Seminar: (Re)Defining Value in Cancer Care: Priorities for Patients, Providers, and Health Systems Panel: International Experience with Health Technology Assessment (HTA) & Lessons for the United States,

Trends of Cost-Effectiveness Over Time from University of Oslo

]]> 193 0 https://cdn.slidesharecdn.com/ss_thumbnails/finaln-200605231914-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Interpreting the Medical Literature /slideshow/interpreting-the-medical-literature/135527765 interpretingthemedicalliteraturefinal-190310205804
Objectives: 1. To give the rationale why staying current on the medical literature is important for patient care, and to explain why this is difficult in practice; 2. To give an overview over study types and forms of bias and other common methodological pitfalls; and 3. To introduce practical ways on how one can 1) get a quick overview over a given clinical areas and 2) stay up-to-date on the hospital medicine literature.]]>
Objectives: 1. To give the rationale why staying current on the medical literature is important for patient care, and to explain why this is difficult in practice; 2. To give an overview over study types and forms of bias and other common methodological pitfalls; and 3. To introduce practical ways on how one can 1) get a quick overview over a given clinical areas and 2) stay up-to-date on the hospital medicine literature.]]> Sun, 10 Mar 2019 20:58:04 GMT /slideshow/interpreting-the-medical-literature/135527765 bengggggg@slideshare.net(bengggggg) Interpreting the Medical Literature bengggggg Objectives: 1. To give the rationale why staying current on the medical literature is important for patient care, and to explain why this is difficult in practice; 2. To give an overview over study types and forms of bias and other common methodological pitfalls; and 3. To introduce practical ways on how one can 1) get a quick overview over a given clinical areas and 2) stay up-to-date on the hospital medicine literature. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/interpretingthemedicalliteraturefinal-190310205804-thumbnail.jpg?width=120&height=120&fit=bounds" /> Objectives: 1. To give the rationale why staying current on the medical literature is important for patient care, and to explain why this is difficult in practice; 2. To give an overview over study types and forms of bias and other common methodological pitfalls; and 3. To introduce practical ways on how one can 1) get a quick overview over a given clinical areas and 2) stay up-to-date on the hospital medicine literature.

Interpreting the Medical Literature from University of Oslo

]]> 312 6 https://cdn.slidesharecdn.com/ss_thumbnails/interpretingthemedicalliteraturefinal-190310205804-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Current Issues in U.S. Health Policy /slideshow/current-issues-in-us-health-policy/74926124 currentissuesinushealthpolicy-170412084231
The seminar will provide a brief overview about the differences between the United States’ health care system and others around the world. The signature legislation of the Obama administration was the Patient Protection and Affordable Care Act of 2012 ("Obamacare") which the new president Trump and the Republican majority in Congress want to repeal and replace. We will explore why health care insurance and delivery is so expensive in the U.S. and the role that geographic variation in costs and quality play. We'll also talk about quality improvement/patient safey as well as the relative absence of health technology assessment and the application of cost-effectiveness analysis in the U.S. when compared to certain other countries (such as Australia or the United Kingdom).]]>
The seminar will provide a brief overview about the differences between the United States’ health care system and others around the world. The signature legislation of the Obama administration was the Patient Protection and Affordable Care Act of 2012 ("Obamacare") which the new president Trump and the Republican majority in Congress want to repeal and replace. We will explore why health care insurance and delivery is so expensive in the U.S. and the role that geographic variation in costs and quality play. We'll also talk about quality improvement/patient safey as well as the relative absence of health technology assessment and the application of cost-effectiveness analysis in the U.S. when compared to certain other countries (such as Australia or the United Kingdom).]]> Wed, 12 Apr 2017 08:42:31 GMT /slideshow/current-issues-in-us-health-policy/74926124 bengggggg@slideshare.net(bengggggg) Current Issues in U.S. Health Policy bengggggg The seminar will provide a brief overview about the differences between the United States’ health care system and others around the world. The signature legislation of the Obama administration was the Patient Protection and Affordable Care Act of 2012 ("Obamacare") which the new president Trump and the Republican majority in Congress want to repeal and replace. We will explore why health care insurance and delivery is so expensive in the U.S. and the role that geographic variation in costs and quality play. We'll also talk about quality improvement/patient safey as well as the relative absence of health technology assessment and the application of cost-effectiveness analysis in the U.S. when compared to certain other countries (such as Australia or the United Kingdom). <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/currentissuesinushealthpolicy-170412084231-thumbnail.jpg?width=120&height=120&fit=bounds" /> The seminar will provide a brief overview about the differences between the United States’ health care system and others around the world. The signature legislation of the Obama administration was the Patient Protection and Affordable Care Act of 2012 ("Obamacare") which the new president Trump and the Republican majority in Congress want to repeal and replace. We will explore why health care insurance and delivery is so expensive in the U.S. and the role that geographic variation in costs and quality play. We'll also talk about quality improvement/patient safey as well as the relative absence of health technology assessment and the application of cost-effectiveness analysis in the U.S. when compared to certain other countries (such as Australia or the United Kingdom).

Current Issues in U.S. Health Policy from University of Oslo

]]> 370 4 https://cdn.slidesharecdn.com/ss_thumbnails/currentissuesinushealthpolicy-170412084231-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Statin Wars /slideshow/statin-wars/41424432 statinwars-141111143844-conversion-gate02
Statin Wars]]>
Statin Wars]]> Tue, 11 Nov 2014 14:38:44 GMT /slideshow/statin-wars/41424432 bengggggg@slideshare.net(bengggggg) Statin Wars bengggggg Statin Wars <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/statinwars-141111143844-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds" /> Statin Wars

Statin Wars from University of Oslo

]]> 8027 10 https://cdn.slidesharecdn.com/ss_thumbnails/statinwars-141111143844-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Decision-analytic Modeling for Clinical and Economic Projections /slideshow/decisionanalytic-modeling-for-clinical-and-economic-projections/39173440 cdmtalk-140916212915-phpapp02
A talk given at M.I.T.'s International Critical Data Marathon]]>
A talk given at M.I.T.'s International Critical Data Marathon]]> Tue, 16 Sep 2014 21:29:15 GMT /slideshow/decisionanalytic-modeling-for-clinical-and-economic-projections/39173440 bengggggg@slideshare.net(bengggggg) Decision-analytic Modeling for Clinical and Economic Projections bengggggg A talk given at M.I.T.'s International Critical Data Marathon <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/cdmtalk-140916212915-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds" /> A talk given at M.I.T.'s International Critical Data Marathon

Decision-analytic Modeling for Clinical and Economic Projections from University of Oslo

]]> 1015 6 https://cdn.slidesharecdn.com/ss_thumbnails/cdmtalk-140916212915-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 An overview of cost modeling and cost effectiveness analysis /slideshow/an-overview-of-cost-modeling-and-cost-effectiveness-analysis/4955624 anoverviewofcostmodelingandcost-effectivenessanalysis-100812142406-phpapp01
]]>
]]> Thu, 12 Aug 2010 14:23:55 GMT /slideshow/an-overview-of-cost-modeling-and-cost-effectiveness-analysis/4955624 bengggggg@slideshare.net(bengggggg) An overview of cost modeling and cost effectiveness analysis bengggggg <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/anoverviewofcostmodelingandcost-effectivenessanalysis-100812142406-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds" />

An overview of cost modeling and cost effectiveness analysis from University of Oslo

]]> 5519 4 https://cdn.slidesharecdn.com/ss_thumbnails/anoverviewofcostmodelingandcost-effectivenessanalysis-100812142406-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Ifmsa Esc2003 /slideshow/ifmsa-esc2003-presentation-936021/936021 ifmsa-esc2003-1232496533683131-1
]]>
]]> Tue, 20 Jan 2009 18:11:03 GMT /slideshow/ifmsa-esc2003-presentation-936021/936021 bengggggg@slideshare.net(bengggggg) Ifmsa Esc2003 bengggggg <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/ifmsa-esc2003-1232496533683131-1-thumbnail.jpg?width=120&height=120&fit=bounds" />

Ifmsa Esc2003 from University of Oslo

]]> 439 4 https://cdn.slidesharecdn.com/ss_thumbnails/ifmsa-esc2003-1232496533683131-1-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 https://cdn.slidesharecdn.com/profile-photo-bengggggg-48x48.jpg?cb=1728120137 www.linktr.ee/bengeisler https://cdn.slidesharecdn.com/ss_thumbnails/esmogeisler-241005091854-62ca1498-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/value-of-immune-checkpoint-blockade-icb-in-microsatellite-stable-mismatch-repair-proficient-mss-pmmr-metastatic-colorectal-cancer-mcrc/272203637 Value of immune checkp... https://cdn.slidesharecdn.com/ss_thumbnails/uscostseminar20240314-240314125803-ced6f34f-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/why-is-health-care-in-the-united-states-so-expensive/266787495 Why Is Health Care in ... https://cdn.slidesharecdn.com/ss_thumbnails/federatedlearningwocoi-221209110357-01d7d1b8-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/federated-learning-254839221/254839221 Federated Learning